Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932904 | 0.86 | IDO1 (0.57) | KMT2ATNIKPOLBIDO1CD74 | |
| SCHEMBL30908758 | 0.84 | IDO1 (0.51) | TSHRLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL606151 | 0.84 | IDO1 (0.51) | TSHRLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3929699 | 0.82 | IDO1 (0.60) | KMT2ATNIKPOLBIDO1CD74 | |
| SCHEMBL2859999 | 0.80 | KDM4E (0.53) | KDM4ETSHRLMNARXFP1MAPK1 | |
| SCHEMBL2860677 | 0.80 | P2RX4 (0.68) | KMT2AMAPK1POLBIDO1TP53 | |
| SCHEMBL3921896 | 0.79 | KMT2A (0.54) | KMT2ATNIKPOLBIDO1CD74 | |
| SCHEMBL5123471 | 0.78 | MIF (0.67) | KDM4EKMT2ATNIKPOLBIDO1 | |
| SCHEMBL9046095 | 0.78 | PLA2G2A (0.46) | TSHRLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL368418 | 0.78 | MIF (0.55) | TSHRLMNANPSR1KMT2ATNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786807-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040927-A1 | Heterocyclic antiviral compounds | HAVCR2, POLR1A, HCCS | KDM4E 2915/4885TSHR 2710/4885LMNA 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.